{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 19,
  "pageCount": 40,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a waterfall chart showing clinical response data and a list of upcoming trial milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/19",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.71
      },
      "kind": "callout",
      "text": "ASCO 2021: data demonstrates Enhertu's strong CNS activity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fc918d0-0832-4a8d-86b5-051879ee32e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.67,
        "y": 0.71
      },
      "kind": "callout",
      "text": "Multiple Phase III trials underway",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53470114-9fb3-4df3-ad2a-735b44a1e0cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.36,
        "y": 0.71
      },
      "kind": "callout",
      "text": "Benefit observed in HER2 1+ and HER2 2+/ISH3-ve by local test",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc457fd2-7f29-49a9-b4db-98abf26e2185",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.36,
        "y": 0.3
      },
      "kind": "chart",
      "text": "BEGONIA: Imfinzi + Enhertu, HER2-low 1L mTNBC waterfall chart",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2289e24a-c57b-4f5c-9065-7f20bda0e431",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.05,
        "y": 0.29
      },
      "kind": "list",
      "text": "Launched in 3L, HER2+ mBC; Total revenue $40m; Strong patient share; EU regulatory approval January 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f2a2bac-9cce-4980-a0d0-d228682db6e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.67,
        "y": 0.29
      },
      "kind": "list",
      "text": "Upcoming Enhertu breast cancer data readouts: H2 2021 DESTINY-Breast03; 2022 DESTINY-Breast02/04; 2022+ Multiple trials",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df24850c-6633-423a-9658-2b67a0f91e1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "title",
      "text": "Enhertu: transforming HER2+ and redefining HER2-low BC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2df26ab-8449-4835-8495-97369b64dec1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "title",
      "text": "Clinical development programme across multiple lines and subtypes",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc01c20e-d689-47f0-9c38-0ec2945b328b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "1a2f4178-c5e6-4394-bf79-d002c14d5830",
      "evidence": "chart/waterfall: BEGONIA: Imfinzi + Enhertu, HER2-low 1L mTNBC waterfall chart",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "6407b6da-054c-43a3-924f-c8af0ea8759b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document showcases AstraZeneca's pipeline and progress in various areas of oncology, providing satisfaction to investors.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}